Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27012475 | 0.88 | LPL (0.51) | LPLLIPGF11HRH3CYP2D6 | |
| SCHEMBL22805607 | 0.85 | HRH3 (0.46) | LPLLIPGF11HRH3 | |
| SCHEMBL18579804 | 0.84 | ALDH1A1 (0.49) | LPLLIPGF11ESR2HRH3 | |
| SCHEMBL3260869 | 0.83 | LPL (0.49) | LPLLIPGF11ESR2HRH3 | |
| SCHEMBL21755926 | 0.83 | HRH3 (0.58) | LPLLIPGF11ESR2HRH3 | |
| SCHEMBL22804314 | 0.82 | LTA4H (0.47) | LPLLIPGF11HRH3 | |
| SCHEMBL18580899 | 0.82 | LPL (0.48) | LPLLIPGF11ESR2HRH3 | |
| SCHEMBL26097644 | 0.82 | LPL (0.41) | LPLLIPGF11ESR2 | |
| SCHEMBL24494978 | 0.80 | SIGMAR1 (0.42) | HRH3ALDH1A1 | |
| SCHEMBL5254853 | 0.80 | LPL (0.55) | LPLLIPGF11ESR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4255906-A1 | NEW INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022117487-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022117487-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, CYP3A4, CYP3A5 | LPL 4800/4885LIPG 4830/4885F11 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.